Insider Selling: Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) VP Sells 12,536 Shares of Stock

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) VP Nathalie Adda sold 12,536 shares of the firm’s stock in a transaction dated Tuesday, January 11th. The shares were sold at an average price of $70.13, for a total transaction of $879,149.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Nathalie Adda also recently made the following trade(s):

  • On Wednesday, December 1st, Nathalie Adda sold 13,523 shares of Enanta Pharmaceuticals stock. The shares were sold at an average price of $86.35, for a total transaction of $1,167,711.05.
  • On Monday, November 1st, Nathalie Adda sold 9,547 shares of Enanta Pharmaceuticals stock. The stock was sold at an average price of $84.89, for a total value of $810,444.83.

Shares of ENTA opened at $60.00 on Friday. The company’s fifty day moving average is $78.71 and its 200-day moving average is $63.78. Enanta Pharmaceuticals, Inc. has a 12 month low of $40.37 and a 12 month high of $102.00. The firm has a market cap of $1.22 billion, a price-to-earnings ratio of -15.35 and a beta of 0.53.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings results on Monday, November 22nd. The biotechnology company reported ($1.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.31) by $0.09. Enanta Pharmaceuticals had a negative net margin of 81.38% and a negative return on equity of 18.53%. The firm had revenue of $23.58 million during the quarter, compared to the consensus estimate of $35.65 million. During the same period in the prior year, the firm earned ($0.55) EPS. Research analysts anticipate that Enanta Pharmaceuticals, Inc. will post -4.24 EPS for the current year.

A number of hedge funds have recently made changes to their positions in ENTA. First Manhattan Co. lifted its holdings in Enanta Pharmaceuticals by 2,820.9% during the 3rd quarter. First Manhattan Co. now owns 969,736 shares of the biotechnology company’s stock valued at $55,090,000 after purchasing an additional 936,536 shares during the last quarter. Armistice Capital LLC grew its position in shares of Enanta Pharmaceuticals by 21.4% during the 2nd quarter. Armistice Capital LLC now owns 2,000,000 shares of the biotechnology company’s stock worth $88,020,000 after buying an additional 352,000 shares during the period. Millennium Management LLC grew its position in shares of Enanta Pharmaceuticals by 490.2% during the 2nd quarter. Millennium Management LLC now owns 140,742 shares of the biotechnology company’s stock worth $6,194,000 after buying an additional 116,897 shares during the period. Assenagon Asset Management S.A. grew its position in shares of Enanta Pharmaceuticals by 481.7% during the 3rd quarter. Assenagon Asset Management S.A. now owns 95,149 shares of the biotechnology company’s stock worth $5,405,000 after buying an additional 78,792 shares during the period. Finally, Krensavage Asset Management LLC grew its position in shares of Enanta Pharmaceuticals by 8.9% during the 2nd quarter. Krensavage Asset Management LLC now owns 939,650 shares of the biotechnology company’s stock worth $41,354,000 after buying an additional 76,802 shares during the period. 95.40% of the stock is owned by hedge funds and other institutional investors.

Several brokerages have recently issued reports on ENTA. Oppenheimer boosted their price objective on shares of Enanta Pharmaceuticals from $55.00 to $73.00 and gave the company a “market perform” rating in a research note on Wednesday, November 24th. Jefferies Financial Group started coverage on shares of Enanta Pharmaceuticals in a research report on Wednesday, October 6th. They set a “buy” rating and a $95.00 price target for the company. Robert W. Baird boosted their price objective on shares of Enanta Pharmaceuticals from $71.00 to $130.00 and gave the stock an “outperform” rating in a report on Monday, November 8th. Zacks Investment Research lowered shares of Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, November 10th. Finally, Royal Bank of Canada cut their target price on shares of Enanta Pharmaceuticals from $74.00 to $72.00 and set a “sector perform” rating on the stock in a research note on Friday, November 19th. Five research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $89.00.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases.

Featured Article: Catch-Up Contributions

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.